Skip to content
Search

Latest Stories

Ranveer Singh starrer Jayeshbhai Jordaar gets a release date

Ranveer Singh will next be seen on the big screen in ’83 which is slated to release on 10th April 2020. After ’83, we will get to see him in YRF’s Jayeshbhai Jordaar. A few weeks ago, the shooting of the film was wrapped up and now the makers have announced the release date of the movie.

Jayeshbhai Jordaar will hit the screens on 2nd Oct 2020. Well, on the same day, Farhan Akhtar starrer Toofan was also slated to release, but now Toofan has been preponed and it will hit the screens on 18th September 2020.


YRF’s spokesperson confirmed the news and said, “In the interest of both films and to ensure an ideal theatrical release, Aditya Chopra & Ritesh Sidhwani have decided to release their films on different dates. YRF will release Jayeshbhai Jordaar on 2nd October and Excel Entertainment will release Toofaan on 18th September 2020.”

However, still, Jayeshbhai Jordaar won’t be getting a solo release. The movie will be clashing with John Abraham starrer Satyameva Jayate 2. It will be interesting to see if this clash will take place or not. Even Vicky Kaushal starrer Sardar Udham was slated to release on the same day, but it has been postponed to 15th January 2021.

Talking about Jayeshbhai Jordaar, the film will mark the Bollywood debut of Shalini Pandey. The actress rose to fame with her performance in Telugu film Arjun Reddy.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less